A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Trial Identifier:	8951-CL-0105
Sponsor:	Astellas Pharma China, Inc.
Start Date:	October 2019
Primary Completion Date:	January 2021
Study Completion Date:	January 2021

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Guangzhou, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.